- Home
- NXG vs FENC Comparison
NXG vs FENC Comparison
Compare NXG & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NXG | FENC |
|---|---|---|
| Founded | 2012 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 415.1M | 366.8M |
| IPO Year | 2010 | 2010 |
Fundamental Metrics
Financial Performance| Metric | NXG | FENC |
|---|---|---|
| Price | $46.95 | $10.55 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $17.20 |
| AVG Volume (30 Days) | 99.6K | ★ 109.4K |
| Earning Date | 01-01-0001 | 11-16-2026 |
| Dividend Yield | ★ 14.78% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.06 |
| Revenue | N/A | ★ $44,642,000.00 |
| Revenue This Year | N/A | $62.55 |
| Revenue Next Year | N/A | $42.10 |
| P/E Ratio | ★ N/A | $169.75 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $42.80 | $5.65 |
| 52 Week High | $65.78 | $13.25 |
Technical Indicators
Market Signals| Indicator | NXG | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 39.09 | 49.88 |
| Support Level | $42.80 | $9.87 |
| Resistance Level | $56.70 | $10.66 |
| Average True Range (ATR) | 2.24 | 0.53 |
| MACD | 0.09 | 0.06 |
| Stochastic Oscillator | 31.17 | 47.83 |
Price Performance
Historical ComparisonAbout NXG NXG NextGen Infrastructure Income Fund of Beneficial Interest
Cushing NextGen Infrastructure Income Fund is a closed-end management investment company. Its investment objective is to seek a high total return with an emphasis on current income. The fund invests at least 80% of its net assets in a portfolio of equity and debt securities of infrastructure companies, including energy infrastructure companies, industrial infrastructure companies, sustainable infrastructure companies and technology and communication infrastructure companies.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.